These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 26598946)

  • 1. Computational oncology--mathematical modelling of drug regimens for precision medicine.
    Barbolosi D; Ciccolini J; Lacarelle B; Barlési F; André N
    Nat Rev Clin Oncol; 2016 Apr; 13(4):242-54. PubMed ID: 26598946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
    Benzekry S; Pasquier E; Barbolosi D; Lacarelle B; Barlési F; André N; Ciccolini J
    Semin Cancer Biol; 2015 Dec; 35():53-61. PubMed ID: 26361213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Precision medicine from experimental to clinical applications in oncology].
    Normanno N
    Recenti Prog Med; 2015 Dec; 106(12):597-600. PubMed ID: 26780068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Combination in Clinical Cancer Treatments.
    Lu DY; Lu TR; Yarla NS; Wu HY; Xu B; Ding J; Zhu H
    Rev Recent Clin Trials; 2017; 12(3):202-211. PubMed ID: 28782482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards Rational Cancer Therapeutics: Optimizing Dosing, Delivery, Scheduling, and Combinations.
    Ferrer F; Fanciullino R; Milano G; Ciccolini J
    Clin Pharmacol Ther; 2020 Sep; 108(3):458-470. PubMed ID: 32557660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the genesis and treatment of cancer: the potential role of physiologically based pharmacodynamics.
    Steimer JL; Dahl SG; De Alwis DP; Gundert-Remy U; Karlsson MO; Martinkova J; Aarons L; Ahr HJ; Clairambault J; Freyer G; Friberg LE; Kern SE; Kopp-Schneider A; Ludwig WD; De Nicolao G; Rocchetti M; Troconiz IF
    Eur J Cancer; 2010 Jan; 46(1):21-32. PubMed ID: 19954965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of individualized dosing in oncology: are we there yet?].
    Joerger M
    Praxis (Bern 1994); 2013 Dec; 103(1):33-9. PubMed ID: 24393821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.
    Zandvliet AS; Schellens JH; Beijnen JH; Huitema AD
    Clin Pharmacokinet; 2008; 47(8):487-513. PubMed ID: 18611060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleoside analogs: ready to enter the era of precision medicine?
    Ciccolini J; Serdjebi C; Le Thi Thu H; Lacarelle B; Milano G; Fanciullino R
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):865-77. PubMed ID: 27218825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer Drug Combinations, How Far We can Go Through?
    Lu DY; Chen EH; Wu HY; Lu TR; Xu B; Ding J
    Anticancer Agents Med Chem; 2017; 17(1):21-28. PubMed ID: 27039923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid learning for precision oncology.
    Shrager J; Tenenbaum JM
    Nat Rev Clin Oncol; 2014 Feb; 11(2):109-18. PubMed ID: 24445514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomics chemotherapy: time for computational decision support.
    Barbolosi D; Ciccolini J; Meille C; Elharrar X; Faivre C; Lacarelle B; André N; Barlesi F
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):647-52. PubMed ID: 25082520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues.
    Karolak A; Markov DA; McCawley LJ; Rejniak KA
    J R Soc Interface; 2018 Jan; 15(138):. PubMed ID: 29367239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational modeling in melanoma for novel drug discovery.
    Pennisi M; Russo G; Di Salvatore V; Candido S; Libra M; Pappalardo F
    Expert Opin Drug Discov; 2016 Jun; 11(6):609-21. PubMed ID: 27046143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the future: how mathematical models inform treatment schedules for cancer.
    Mathur D; Barnett E; Scher HI; Xavier JB
    Trends Cancer; 2022 Jun; 8(6):506-516. PubMed ID: 35277375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics and breast cancer management: current status and perspectives.
    Ciccolini J; Fanciullino R; Serdjebi C; Milano G
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):719-29. PubMed ID: 25690018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision Medicine in Oncology Pharmacy Practice.
    Saadeh C; Bright D; Rustem D
    Acta Med Acad; 2019 Apr; 48(1):90-104. PubMed ID: 31264437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mathematical modeling of efficacy and safety for anticancer drugs clinical development.
    Lavezzi SM; Borella E; Carrara L; De Nicolao G; Magni P; Poggesi I
    Expert Opin Drug Discov; 2018 Jan; 13(1):5-21. PubMed ID: 28972401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative methods for analyzing big data in precision medicine.
    Gligorijević V; Malod-Dognin N; Pržulj N
    Proteomics; 2016 Mar; 16(5):741-58. PubMed ID: 26677817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside.
    Yamazaki S; Spilker ME; Vicini P
    Expert Opin Drug Metab Toxicol; 2016; 12(3):253-65. PubMed ID: 26799750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.